The Best Peptides for Brain and Cognitive Function: A 2026 Evidence Review

Interest in peptides for cognition has grown alongside the broader peptide boom — a global peptide therapeutics market valued at roughly $48.1 billion in 2025 and projected to reach $93.5 billion by 2032. While most of that attention focuses on weight loss and tissue repair, a smaller but devoted research community has spent decades studying short peptides that appear to influence learning, memory, mood and resilience to stress.

A peptide is simply a short chain of amino acids — by convention 2 to 50 — joined by peptide bonds. (If you are new to the category, our explainer on what peptides are covers the basics.) The peptides discussed in this article are sometimes called "nootropic peptides" or "cognitive peptides," but that label is informal. Unlike caffeine or amphetamines, these molecules generally do not produce acute stimulation. Instead, they are studied for their ability to modulate the brain's own growth-factor and neurotransmitter systems over days to weeks.

This distinction matters. The headline mechanisms — increases in BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor) and synaptic plasticity — are mechanisms of slow structural change, not instant alertness. That also makes their effects harder to measure and easier to overstate.

This article reviews five peptides most frequently discussed in the nootropic context: Semax, Selank, Dihexa, PE-22-28 and Epithalon. For each, we summarize the proposed mechanism, the actual state of the evidence, and the limitations you should weigh. None of these compounds is an approved cognitive treatment, and the quality of evidence ranges from "decades of regional clinical use" to "a handful of rodent studies."

Medical disclaimer: This content is for educational purposes only and is not medical advice. Most peptides covered here are classified as research compounds and are not approved for human use as nootropics. Always consult a qualified healthcare professional before considering any peptide, and review our medical disclaimer.

To evaluate these peptides honestly, it helps to understand the biology they are claimed to target. Three overlapping systems come up repeatedly: neurotrophic factors, neuroplasticity, and neurotransmitter modulation.

Neurotrophic factors are signaling proteins that support neuron survival, growth and differentiation. The most discussed is BDNF, which binds the TrkB receptor and drives long-term potentiation — the cellular process widely considered a substrate of learning and memory. NGF plays an analogous role for certain neuron populations, particularly cholinergic neurons relevant to attention and memory. A third factor, HGF (hepatocyte growth factor), acting through its receptor c-Met, has emerged as a powerful regulator of synapse formation in the hippocampus — and is central to how Dihexa is thought to work.

Neuroplasticity is the brain's capacity to reorganize by forming, strengthening and pruning synaptic connections. Peptides that raise neurotrophic signaling are hypothesized to increase the brain's plasticity "set point," potentially improving the ability to learn or to recover after stress or injury. Importantly, more plasticity is not automatically better; the brain tightly regulates these processes for good reason.

Neurotransmitter modulation rounds out the picture. Selank, for instance, appears to influence GABAergic and serotonergic tone and the expression of enkephalin-degrading enzymes, producing anxiolytic effects without the sedation or dependence associated with benzodiazepines. PE-22-28 targets the TREK-1 potassium channel, a player in mood regulation.

A practical caveat ties these mechanisms together: peptides are typically fragile in the bloodstream, with half-lives measured in minutes, and many do not readily cross the blood–brain barrier. This is precisely why several of these compounds are delivered intranasally (Semax, Selank) or were chemically engineered for stability and lipophilicity (Dihexa). When you see claims of dramatic potency, ask whether the molecule can actually reach the brain in the form and dose described.

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone — specifically an analog of ACTH(4–10) — with a Pro-Gly-Pro extension added to improve metabolic stability. It was developed in Russia, where it has been used clinically for decades for indications including ischemic stroke and cognitive disorders, and it appears on Russia's list of essential medicines. Outside Russia, however, it remains unapproved and is sold as a research compound.

Mechanistically, Semax is one of the better-characterized peptides on this list. Rodent research has shown that Semax administration increases the expression of BDNF and its receptor TrkB in the hippocampus, a region central to memory formation. It is also reported to modulate the dopaminergic and serotonergic systems and to exert neuroprotective and antioxidant effects, which is part of the rationale for its use in acute ischemic stroke protocols in Russia.

Reported subjective effects among users include improved focus, mental clarity and verbal fluency, typically without the jittery overstimulation of classic stimulants. Semax is most commonly administered as an intranasal solution, which bypasses gastrointestinal degradation and offers a partial route toward the central nervous system. A more potent variant, N-acetyl Semax amidate, is also widely discussed.

The key limitation is the evidence base. Most controlled studies are Russian, often older, and many are not easily accessible or replicated in large international randomized trials. The stroke and neuroprotection literature is the strongest, while the "healthy person nootropic" use case rests largely on extrapolation and anecdote. Treat Semax as a peptide with genuine pharmacological plausibility but incomplete modern validation.

Selank is the cognitive peptide most often paired with Semax, and the two share a common origin story. Selank is a synthetic analog of the endogenous immunomodulatory peptide tuftsin, again stabilized with a Pro-Gly-Pro extension. Like Semax, it was developed in Russia and is used there primarily as an anxiolytic.

What distinguishes Selank from conventional anti-anxiety drugs is its proposed mechanism. Rather than acting directly on GABA-A receptors like a benzodiazepine, Selank appears to modulate the expression of genes involved in GABAergic and serotonergic neurotransmission, and it inhibits enzymes that degrade enkephalins, prolonging the activity of these endogenous opioid-like peptides. The practical consequence reported in the literature is anxiolysis without the sedation, cognitive dulling or dependence liability associated with benzodiazepines.

Selank has also been studied for effects on BDNF expression and for modulation of inflammatory cytokines, reflecting tuftsin's immunomodulatory heritage. Because anxiety and stress impair working memory and attention, the cognitive benefit users describe — calmer, clearer thinking under pressure — may be downstream of its anxiolytic and stabilizing effects rather than a direct memory-enhancing action.

As with Semax, Selank is typically used intranasally and is frequently stacked with Semax on alternating schedules so that one supports calm and the other supports drive. And as with Semax, the caveats are the same: the human evidence is largely regional, older and not yet replicated in large Western trials, and Selank is not approved as a nootropic outside its country of origin. It should be regarded as a research peptide.

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is the most provocative entry on this list — and the one to approach with the most skepticism. It is a small, metabolically stabilized analog derived from angiotensin IV, engineered by researchers at Washington State University to be lipophilic enough to cross the blood–brain barrier and to resist rapid breakdown.

Its proposed mechanism sets it apart. Rather than primarily raising BDNF, Dihexa is reported to act through the HGF/c-Met system, augmenting hepatocyte growth factor signaling to drive synaptogenesis — the formation of new synaptic connections. The headline finding from preclinical work is striking: in some assays Dihexa was reported to be several orders of magnitude more potent than BDNF itself at facilitating synapse formation, and it improved performance in rodent models of cognitive impairment, including Alzheimer's-type models.

If those figures sound almost too good, that is the appropriate reaction. The evidence for Dihexa is essentially confined to preclinical, mostly rodent and in vitro studies from a small number of research groups. There are no published large human clinical trials establishing efficacy or — critically — long-term safety. The same synaptogenic and growth-factor potency that excites researchers also raises a legitimate theoretical concern: pathways that stimulate cell growth and proliferation warrant careful scrutiny for unintended effects, and this has not been characterized in humans.

Dihexa is sold strictly as a research chemical and is not approved for human use anywhere. It is best understood as an interesting pharmacological tool with a remarkable mechanism on paper, but one whose human risk–benefit profile is genuinely unknown. The gap between its preclinical promise and its clinical validation is the widest of any peptide here.

PE-22-28 is a shortened analog of spadin, a peptide naturally produced when the sortilin receptor's propeptide is cleaved. Its mechanism is distinct from the neurotrophic-factor story that dominates the rest of this list: PE-22-28 is studied as an inhibitor of the TREK-1 potassium channel.

TREK-1 has attracted interest because mice lacking the channel show a "depression-resistant" phenotype, and pharmacological blockade of TREK-1 produces antidepressant-like effects in animal models. PE-22-28 was developed as a more stable, more potent spadin derivative with better in vivo durability. In rodent studies it has shown rapid antidepressant-like activity and, relevant to cognition, has been associated with increased markers of neurogenesis and synaptogenesis in the hippocampus, including effects linked to BDNF signaling.

The cognitive angle for PE-22-28 is therefore mostly indirect and exploratory: an antidepressant mechanism that also appears to promote hippocampal plasticity. Because depression and chronic stress measurably degrade memory and executive function, a compound that addresses mood while supporting neurogenesis is conceptually attractive.

The honest assessment, however, is that PE-22-28 sits at an early research stage. The data are preclinical, human evidence is absent, and its pharmacology — while mechanistically interesting — has not been validated in clinical settings. It is a research peptide of scientific interest rather than an established nootropic, and any claims about cognitive enhancement in humans are speculative at this point.

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — modeled on epithalamin, a natural extract of the pineal gland. It is the outlier of this group: rather than being framed primarily as a focus or memory enhancer, Epithalon is studied in the context of aging, circadian regulation and cellular longevity, with cognitive effects positioned as a possible downstream benefit.

Its most discussed mechanism is the reported activation of telomerase, the enzyme that maintains the protective telomere caps on chromosomes. Russian research groups, notably those led by Vladimir Khavinson, have reported that Epithalon can extend the replicative capacity of somatic cells in culture and influence melatonin and circadian rhythm regulation via the pineal gland. Because sleep quality and circadian health are tightly linked to memory consolidation and overall cognitive performance, this is the most plausible indirect route to any cognitive benefit.

The longevity claims, however, are among the most heavily hyped in the peptide space and the least supported by rigorous, independent human data. Much of the foundational research is regional, older, and not consistently replicated by outside laboratories. Telomerase activation is also a double-edged concept: while telomere maintenance is associated with cellular youth, inappropriate telomerase activity is a hallmark of many cancers, which is a reason for caution rather than enthusiasm in the absence of long-term human safety data.

For the purposes of this article, Epithalon is best categorized as a research peptide of interest for aging and circadian biology, with cognitive benefits that are speculative and indirect. It is not an approved therapy, and the gap between its popular reputation and its evidence base is substantial.

Within the research community, "stacking" — combining peptides to target complementary mechanisms — is a common topic. The most established conceptual pairing is Semax with Selank: Semax for drive, focus and neurotrophic support, Selank for anxiolysis and emotional stability. Because the two address different problems (stimulation versus calm), they are often discussed as a balanced pair rather than redundant additions. For the general principles and pitfalls of combining peptides, see our guide to peptide stacking.

Beyond that pairing, rational stacking quickly outruns the evidence. There are no human trials testing Dihexa, PE-22-28 or Epithalon in combination with one another or with Semax/Selank. Any proposed multi-peptide protocol is therefore extrapolation from individual mechanisms, not validated practice. Combining several bioactive compounds with overlapping or unknown effects also multiplies the uncertainty around interactions and side effects.

A few sensible principles apply regardless of the specific stack. First, introduce one compound at a time so that effects — and adverse effects — can be attributed correctly. Second, respect the difference between mechanisms: stacking two BDNF-modulating peptides is not obviously additive and may simply increase risk. Third, recognize that more plasticity-promoting signaling is not automatically beneficial; the brain regulates these pathways deliberately.

It is also worth situating these compounds against more conventional and better-evidenced cognitive supports — sleep, exercise (itself a potent BDNF inducer), nutrition and stress management — which carry far less uncertainty. Peptides, if considered at all, belong in the experimental tier of that hierarchy. If you want a broader survey of the category, our overview of the best peptides overall places cognitive peptides in context alongside repair and metabolic peptides.

The dosing figures circulated for these peptides come from research protocols, regional clinical practice (for Semax and Selank) and community reports — not from internationally accepted prescribing guidelines, because none exist for nootropic use. The table below summarizes commonly cited ranges and routes for educational reference only. It is not a recommendation to use these compounds.

On safety, the short answer is that long-term human safety data are limited to absent for all five, and entirely absent for Dihexa, PE-22-28 and Epithalon as cognitive agents. Semax and Selank have the most reassuring track record by virtue of decades of clinical use, with reported side effects generally mild. But the absence of reported problems in regional use is not the same as a rigorous safety profile, and no peptide should ever be described as having "no side effects."

Quality control is a separate, serious concern. Because these are sold as research chemicals, purity, dosing accuracy and sterility vary widely between suppliers, and the FDA has issued warning letters to companies marketing unapproved peptide products. Contamination or mislabeling adds risk on top of the pharmacological unknowns. Tools such as a reconstitution calculator are sometimes used to manage measurement, but they do not address the underlying questions of legality, purity or appropriateness.

Legal status varies considerably by jurisdiction. In the United States and European Union, most of these peptides are classified for research use only and are not approved for human consumption as nootropics. Several are monitored or prohibited in competitive sport under anti-doping frameworks. Possession and import rules differ from country to country, so the legal picture where you live may not match what online vendors imply. Consult both a healthcare professional and the regulations applicable to your jurisdiction before acting on any of this information.

If there is a single takeaway, it is that the gap between mechanism and proof is the defining feature of this category. Each of these peptides has a plausible, sometimes elegant mechanism — BDNF and NGF support, HGF-driven synaptogenesis, TREK-1 modulation, telomerase activation. But plausible mechanisms are abundant in pharmacology; validated, durable, safe cognitive benefit in humans is rare.

Ranked roughly by weight of evidence, Semax and Selank stand apart for their decades of regional clinical use and reasonably characterized mechanisms, even though large modern international trials are still missing. Epithalon has a meaningful body of regional research but is oriented toward aging rather than acute cognition, with heavily hyped and weakly substantiated longevity claims. Dihexa and PE-22-28 are the most mechanistically exciting and the least validated — fascinating in the laboratory, unproven and largely uncharacterized for safety in people.

For most people interested in cognition, the highest-yield interventions remain the unglamorous ones: consistent sleep, regular aerobic exercise, a good diet and effective stress management — all of which influence the very same BDNF and plasticity pathways these peptides target, with far better evidence and far lower risk. Peptides, if they have any role at all, sit firmly in the experimental tier and demand professional medical guidance.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. None of the peptides discussed is approved by the FDA or EMA as a cognitive enhancer; most are research compounds not approved for human use, and their legal status varies by jurisdiction. Always consult a qualified healthcare professional before considering any peptide. See our full medical disclaimer for details.